Pharma market rebounds, asthma drug top seller – Newz9

NEW DELHI: After months of sluggish gross sales, sturdy demand for derma and cardiac medication drove the organized pharma retail market to double-digit progress in Nov, with heavy air pollution in a number of elements of the nation boosting Foracort gross sales.
The remedy, used for asthma and respiratory points, topped the market in Nov with gross sales of Rs 82 crore, based on the most recent knowledge culled by TOI from IQVIA.
Foracort assumed the top slot in Nov with a progress of two%, whereas antibiotic Augmentin ranked second with a progress of 9% registering Rs 76 crore gross sales, and antidiabetic remedy Glycomet GP, ranked third, was virtually flat at Rs 69 crore.

In phrases of therapies, urology led the expansion with 18% rise, whereas the derma, cardiac, and ache-reduction segments adopted with progress charges of 16%, 13%, and 13%, respectively.
Further, ache-reduction remedy Zerodol SP posted a progress of twenty-two%, whereas others which grew over 20% month-on-month embrace Ryzodeg, Rosuvas, Cilacar, Rybelsus and Duphalac.
Sun Pharma continued to steer the pack with a share of 8% within the total pharma retail market valued at Rs 2,28,059 crore. Cipla and Dr Reddy’s additionally elevated their share month on month.
During the month, each acute – primarily painkillers and anti-infectives – and persistent remedy, these prescribed for lengthy-time period illnesses, posted a double-digit progress of 11% every.
“After a lull for the last three months, industry volumes reported positive growth of 3.5%”. Rebound in progress for anti-infectives was led by key molecules like amoxicillin+clavulanic acid and ceftriaxone, pantoprazole+domperidone mixture was important progress driver for gastro- intestinal remedy, cough syrups, formoteral+budesonide and levocetirizine+montelukast drove progress in respiratory therapies,” an analyst from ICICI stated.
Domestic corporations registered progress of almost 11%, whereas MNCs grew simply over 10%.
In 2025, the market will proceed to develop by excessive-single digits, led by worth improve and new launches, whereas quantity progress stays muted, an analyst from HSBC instructed TOI. “In 2025, we assume Indian companies will start their journey in GLP-1 (Glucagon-like peptide-1) drugs with the launch of generic liraglutide,” he added.
GLP-1 is a hormone that helps management blood sugar ranges and performs a job in weight administration. Globally, MNCs together with Novo Nordisk and Eli Lilly have launched blockbuster medication for weight problems and diabetes, that are anticipated to be launched in India over the subsequent few years.